Browse the evidence

Abbott measurements were 12.9±0.1 mg/dl lower than Dexcom (p<0.0001).

Clinicians should be aware that different CGMs may provide varying glucose readings.

Mathematical models can help design and predict the results of key new experiments to fill knowledge gaps.

Practitioners can use mathematical models to inform the design of experiments aimed at addressing knowledge gaps in obesity and metabolism.

The reanalysis ignored the within-participant, repeated-measures structure of the data.

Understanding the importance of proper statistical methods is crucial for accurate dietary research interpretation.

The reanalysis reported incorrect statistical comparisons and optimistic p-values.

Practitioners should critically evaluate statistical results in dietary studies to avoid misinterpretation.

There is no current method to quantitatively estimate the permanent changes in diet or physical activity required to prevent weight regain.

Practitioners should be aware of the lack of quantitative tools for estimating necessary lifestyle changes for weight maintenance.

More people around the world now have obesity than suffer from starvation.

This indicates a need for urgent public health interventions to address obesity.

The energy available in the United States food supply increased much more than population needs.

This suggests that dietary guidelines should address energy intake relative to needs.

There is a need for reform in laws governing corporations to hold them accountable.

Practitioners should engage in advocacy for corporate accountability in food marketing.

70% of respondents disagreed that current SNAP benefit levels were adequate to maintain a healthy diet.

Practitioners should consider advocating for increased SNAP benefits to support healthier diets.

A total of 1026 girls have been flagged for potential eligibility in the RCT over a 2-year period.

This indicates the feasibility of recruiting participants for dietary studies in PCOS.

Medication use was the most frequent reason for exclusion from the study, affecting 26% of flagged girls.

Practitioners should be aware that medication use may limit eligibility for dietary interventions in PCOS.

Receiving e-messages had no significant effect on adherence to low-carbohydrate or low-fat diets.

The e-message intervention did not enhance adherence to specific dietary plans, indicating a need for more effective strategies.

Households in low-income countries spend a considerable proportion of their income on food, approximately half.

Understanding food expenditure can help in designing interventions for better nutrition.

The database serves as a tool for evaluating evidence linking specific fibers with health outcomes.

Practitioners can use this database to find evidence-based information on dietary fibers.

Tirzepatide has been registered in multiple countries including the USA, UK, Canada, and Saudi Arabia.

This information is relevant for healthcare providers regarding the availability of Tirzepatide.

In 46% of the 104 studies analyzed, there was no information on the proportion of older individuals.

Practitioners should be cautious when applying findings from studies that do not include older populations.

Older patients were mostly underrepresented in the studies analyzed.

Findings may not be generalizable to older patients due to their underrepresentation.

The analysis found no significant differences in efficacy and safety of the drugs between age groups.

Efficacy and safety of GLP-1 receptor agonists and SGLT2 inhibitors appear consistent across age groups.

Major complication rates did not differ significantly between AOM users and the control group.

AOMs may be safely used preoperatively without increasing complication risks.

No significant differences in readmission rates, BMI, and total weight loss were observed at 6, 12, and 18 months of follow-up between groups.

Long-term outcomes may not be significantly improved by preoperative AOM use.

46% of the 104 studies analyzed lacked information on the proportion of older individuals.

Practitioners should be aware of the lack of representation of older patients in clinical trials when prescribing these medications.

Older patients were mostly underrepresented in clinical trials for GLP-1 receptor agonists and SGLT2 inhibitors.

Practitioners should consider the implications of underrepresentation when treating older patients.

No significant differences in efficacy and safety of the drugs were found between age groups.

Practitioners can consider that the efficacy and safety of these medications do not significantly vary with age.

Many individuals do not continue therapy indefinitely.

Clinicians should be aware of potential adherence issues with incretin therapy.